Provided by Tiger Trade Technology Pte. Ltd.

Guardant Health Inc.

163.71
+0.91500.56%
Volume:532.93K
Turnover:86.42M
Market Cap:21.97B
PE:-46.72
High:164.38
Open:161.95
Low:158.36
Close:162.79
52wk High:191.05
52wk Low:61.00
Shares:134.20M
Float Shares:129.78M
Volume Ratio:0.49
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5037
EPS(LYR):-3.3203
ROE:-4584.47%
ROA:-18.07%
PB:-98.57
PE(LYR):-49.30

Loading ...

Nov 18, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 13, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 13, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 12, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 08, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 06, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 06, 2024

Major Issues Report

Form 8-K - Current report
Oct 24, 2024

Major Issues Report

Form 8-K - Current report
Oct 07, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Oct 07, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Aug 23, 2024

Major Issues Report

Form 8-K - Current report
Aug 07, 2024

Major Issues Report

Form 8-K - Current report
Aug 07, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 29, 2024

Major Issues Report

Form 8-K - Current report
Jul 19, 2024

Major Issues Report

Form 8-K - Current report
Jun 14, 2024

Major Issues Report

Form 8-K - Current report
Jun 05, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 31, 2024

Major Issues Report

Form 8-K - Current report
May 24, 2024

Major Issues Report

Form 8-K - Current report
May 09, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]